



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/820,777	04/09/2004	Winston T.K. Cheng	MR2723-365	8832
570	7590	08/21/2007	EXAMINER	
AKIN GUMP STRAUSS HAUER & FELD L.L.P. ONE COMMERCE SQUARE 2005 MARKET STREET, SUITE 2200 PHILADELPHIA, PA 19103			WILSON, MICHAEL C	
		ART UNIT	PAPER NUMBER	
		1632		
		MAIL DATE	DELIVERY MODE	
		08/21/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)
	10/820,777	CHENG ET AL.
	Examiner	Art Unit
	Michael C. Wilson	1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 29 June 2007.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 19-36 is/are pending in the application.
 4a) Of the above claim(s) 32-36 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 19-31 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____. _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 6-29-07 has been entered.

Claims 1-18 have been canceled. Claims 19-36 have been added.

Election/Restrictions

Newly submitted claims 32-36 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

The milk (claims 32-34) is patentably distinct from the transgenic and method of making the transgenic. Inventions are related as mutually exclusive species in an intermediate-final product relationship. Distinctness is proven for claims in this relationship if the intermediate product is useful to make other than the final product, and the species are patentably distinct (MPEP § 806.05(j)). In the instant case, the intermediate product (transgenic) is deemed to be useful as food and the inventions are deemed patentably distinct because there is nothing on this record to show them to be obvious variants. Claims 32-34 do not clearly set forth the milk collected has the FVIII protein.

The protein (claims 35-36) is patentably distinct from the transgenic and method of making the transgenic. In this case, the protein can be made by other means and does not have to be isolated from milk of a transgenic.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 32-36 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claims 19-31 are under consideration as they relate to transgenics and methods of making transgenics.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Applicant's arguments filed 6-29-07 have been fully considered but they are not persuasive.

Claim Objections

Claims 20-24 are objected to because of the following informalities: The use of "a" in claims 20-24 is inappropriate because the claims are further limiting proteins or DNA sequences to "the" protein or DNA sequence of SEQ ID NO: 13, 1, 14, 2, or 15. Use of "a" also implies using a portion of SEQ ID NO: 13, 1, 14, 2 or 15, which does not have support in the specification as originally filed (see new matter rejection). Appropriate correction is required.

Claim Rejections - 35 USC § 112

Claims 19-31 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The phrases “mammary gland-specific signal peptide” and “lacking innate signal peptide” in claim 19 are new matter. Support cannot be found in the citations provided. The specification only discusses mammary gland-specific promoters on pg 9, line 8.

Use of “a” in claims 20-24 implies using a portion of SEQ ID NO: 13, 1, 14, 2 or 15, which does not have support in the specification as originally filed.

The phrase “about 50 mg” (claim 27) does not have support in originally claim 16, which is limited to an amount that “can reach 50 mg”, which does not have the same scope.

The phrase “as the non-human transgenic mammal” in claim 28 does not have support. The specification only describes implanting the embryo into female of the same species as the embryo.

Indefiniteness

Claims 19-31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 19 is unclear because the phrase "lacking its innate signal peptide" (claim 19) is unclear. It is unclear to what "innate" refers. In particular, it cannot be determined if the "innate" signal peptide must be deleted in addition to the B-domain or if the "innate" signal peptide refers to a portion of the B-domain that has been deleted.

Claim 24 is indefinite because SEQ ID NO: 15 more accurately further limits the B-domain deleted human clotting factor VIII polypeptide not the recombinant polypeptide.

Claim 27 is indefinite because the metes and bounds of what applicants consider "about 50 mg" cannot be determined.

Claim 28 is indefinite because "as the non-human transgenic mammal" should be --as the embryo-- because the embryo and recipient female must be of the same species.

Rejections - 35 USC § 103

Claims 19-21, 24-26 and 28-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen (Transgenic Research, 11:257-268, 2002) in view of Soukharev (Blood Cells, Molecules and Diseases, 28:234-248, 2002) and supported by Lubon (US Patent 6,255,554, Issued July 3, 2001).

Chen made a transgenic mouse comprising a vector encoding 7.2 kb of hFVIII coding region operably linked to the 2.0 kb bovine a-LA promoter and 19 amino acid bovine a-LA signal peptide sequence (pg 258, col. 2, first full paragraph; paragraph bridging pg 258-259). The 19 amino acid leader sequence of Chen is the 19 amino acid signal peptide of SEQ ID NO: 13 and encoded by SEQ ID NO: 1. The mouse was

made by introducing the transgene construct (i.e. expression cassette) into an embryo, implanting the embryo into a recipient female, allowing the embryo to develop to term, and testing the resulting offspring and identifying mice that secreted hFVIII in milk by RT-PCR and analysis of the milk for protein (paragraph bridging columns 1 and 2 of pg 263). Chen did not delete the B-domain of hFVIII.

However, Soukharev suggested making transgenic mammals expressing B-domain deleted FVIII to improve yield of FVIII (pg 241, paragraph bridging columns 1 and 2). “[A]nother approach to improve recombinant FVIII molecule is to introduce modifications to improve its effective secretion from FVIII-expressing cell” (page 239, col. 1, paragraph 1, lines 1-4) and that “removal of the B domain...was found to dramatically improve the yield of FVIII” (page 237, col. 2, lines 3-6). Soukharev taught “an attractive possibility to increase the yield of rFVIII is to produce a biologically active form of FVIII by coexpressing its heavy and light chains” (page 239, paragraph 2, line 1 to col. 2, line 2). The phrase “a B-domain deleted hFVIII polypeptide of SEQ ID NO: 15” encompasses any B-domain deleted hFVIII protein of SEQ ID NO: 15. The nucleic acid sequence encoding the B-domain deleted hFVIII taught by Soukharev encodes “a B-domain deleted hFVIII polypeptide of SEQ ID NO: 15” as in claim 24. Without evidence to the contrary, the B-domain deleted hFVIII taught by Soukharev inherently produces a hFVIII comprising a light chain (A3-C1-C2 domain) and a heavy chain (A1-A2 domain) operably linked by a junction as in claim 25.

Thus, it was obvious to those of ordinary skill in the art at the time of filing to make a transgenic mouse encoding hFVIII as taught by Chen, wherein the hFVIII had a

deletion in the B-domain as taught by Soukharev. Soukharev provides motivation on pg 241, lines 1-5. Those of skill would have a reasonable expectation of successfully improving the yield of FVIII as suggested by Soukharev because results in vitro improved the yield (pg 237, "Genetic engineering to improve the yield of recombinant FVIII). Lubon provides further evidence that fragments of hFVIII could be made in a non-human transgenic animal (claim 1 of Lubon).

Thus, Applicants' claimed invention as a whole is *prima facie* obvious in the absence of evidence to the contrary.

Response to arguments

Applicants argue given the unpredictability of transgenics those of ordinary skill would not have known whether a transgenic mammal that secretes BDD-rFVIII in milk could ever be made. Applicants provide a declaration by Chuan-Mu Chen, which states in vitro results cannot be reproduced in vivo and provides details about FVIII secretion into the milk. Applicants' arguments and the declaration are not persuasive. Those of skill would have a reasonable expectation of successfully improving the yield of FVIII as suggested by Soukharev because results in vitro improved the yield (pg 237, "Genetic engineering to improve the yield of recombinant FVIII). Lubon provides further evidence that fragments of hFVIII could be made in a non-human transgenic animal (claim 1 of Lubon). The increased yield observed by applicants' as compared to the yield obtained by Chen was predicted by Soukharev. The yield observed by applicants is not unexpected.

Claims 19-26 and 28-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen (Transgenic Research, 11:257-268, 2002) in view of Soukharev (Blood Cells, Molecules and Diseases, 28:234-248, 2002) and supported by Lubon (US Patent 6,255,554, Issued July 3, 2001) as applied to claims 19-21, 24-26 and 28-31 above, and further in view of DeBoer (US Patent 5,633,076, Issued May 27, 1997).

The combined teachings of Chen and Soukharev taught making a transgenic mouse comprising a vector encoding B-domain deleted hFVIII coding region operably linked to the 2.0 kb bovine a-LA promoter and 19 amino acid signal peptide sequence (Chen - pg 258, col. 2, first full paragraph; paragraph bridging pg 258-259; Soukharev - pg 241, paragraph bridging columns 1 and 2; page 239, col. 1, paragraph 1, lines 1-4; page 237, col. 2, lines 3-6; page 239, paragraph 2, line 1 to col. 2, line 2; see 103 rejection above). The 19 amino acid leader sequence of Chen is the 19 amino acid signal peptide of SEQ ID NO: 13. The mouse secreted hFVIII in milk (paragraph bridging columns 1 and 2 of pg 263). The combined teachings of Chen and Soukharev did not teach replacing the 19 amino acid a-LA signal peptide of SEQ ID NO: 13 with the 15 amino acid α -S1 casein signal peptide of SEQ ID NO: 14 (encoded by SEQ ID NO: 2).

However, DeBoer taught a nucleic acid construct comprising various nucleic acid elements for the optimization of producing recombinant protein in the milk of transgenic animals, said recombinant protein including FVIII (col. 7, line 12) including the alpha S1 casein secretion signal peptide (col. 7, lines 18-27). DeBoer also taught using the

alpha-lactalbumin, whey acidic protein, beta-casein and alpha S1 casein (col. 2, line 53 to col. 3, line 5).

Thus, it was obvious to make a transgenic mouse encoding B-domain deleted hFVIII operably linked to the as taught by the combined teachings of Chen and Soukharev, wherein the α-lactalbumin signal peptide of SEQ ID NO: 13 was replaced with the α-S1 casein signal peptide of SEQ ID NO: 14 (encoded by SEQ ID NO: 2). One of ordinary skill in the art would have been motivated to use the α-S1 casein signal peptide instead of the α-lactalbumin signal peptide to increase secretion of hFVIII into the milk. Those of skill would have a reasonable expectation of successfully swapping signal peptides in view of the teachings of DeBoer. Lubon provides further evidence that signal peptides could be readily swapped to increase secretion into the milk of a non-human transgenic animal. Lubon states the “[i]mportant to the present invention are regulatory sequences that direct secretion of proteins into milk and/or other body fluids of the transgenic animal. In this regard, both homologous and heterologous regulatory sequences are useful in the invention. Generally, regulatory sequences known to direct the secretion of milk proteins, such as either signal peptides from milk proteins or the nascent target polypeptide, can be used...” (col. 6, lines 45-52).

Thus, Applicants' claimed invention as a whole is *prima facie* obvious in the absence of evidence to the contrary.

Response to arguments

Applicants argue DeBoer fails to compensate for the deficiencies of Chen, Soukharev and Lubon. Applicants' argument is not persuasive. DeBoer provides

adequate guidance to use the α -casein signal peptide, which is all that is required.

Motivation to use the α -S1 casein signal peptide instead of the α -lactalbumin signal peptide is to increase secretion of hFVIII into the milk.

Conclusion

No claim is allowed.

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached at the office on Monday, Tuesday, Thursday and Friday from 9:30 am to 6:00 pm at 571-272-0738.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Peter Paras, can be reached on 571-272-4517.

The official fax number for this Group is (571) 273-8300.

Michael C. Wilson



MICHAEL WILSON
PRIMARY EXAMINER